Д.Гантуяа
Loading...
Товч нэр
Д.Гантуяа
Бүтэн нэр
Дорж Гантуяа
Латин нэр
Dorj Gantuya
Албан тушаал
Тэнхимийн эрхлэгч
Эрдмийн цол
Дэд профессор
Боловсролын зэрэг
Доктор (Ph.D)
Харьяалал
ORCID
Scopus Author ID
6 results
Now showing 1 - 6 of 6
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, National surveillance of antibiotic consumption in MongoliaBackground: It is well-known that the use of antimicrobial agents and AMR are inter-related. Only limited data are available in regards with actual consumption from low-income countries where a high prevalence of AMR are being reported. Hence, the current study aimed to provide and analyze the antibiotic consumption at the national level from Mongolia. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Health and Wellbeing of Older People in Mongolia: A Population-Based Survey(SAGE Publications, 2025-03) ;Cumming, Robert G; ;Yiengprugsawan, Vasoontara Sbirakos ;Dracakis, Jocelyn GThe objectives of this survey were to describe the health of older Mongolians and compare those living in rural areas, urban apartment areas, and urban ger areas in the capital, Ulaanbaatar. A population-based random sample survey of 975 people aged 60 years and older was conducted in 2017 to 2018. Data were collected using methods of the World Health Organization's Study on global AGEing and adult health. The most common chronic self-reported health conditions were hypertension (65%), arthritis (40%), and angina (23%). Most (80%) reported they were satisfied with life and the mean World Health Organization Quality of Life score on a scale of 0 to 100 was 70.6, which is relatively high. There was a higher prevalence of activities of daily living (ADLs) disability in rural areas, with 17% reporting severe difficulty with at least one ADL. High levels of disability in rural areas suggest the need for improved health and social services, including housing, for older people living outside Ulaanbaatar. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Availability, affordability and costs of pediatric medicines in Mongolia(Springer Science and Business Media LLC, 2018-05) ;Dorj, Gereltuya ;Sunderland, Bruce ;Sanjjav, Tsetsegmaa; BACKGROUND: The Essential Medicines List for Children (EMLc) was developed by the World Health Organization (WHO) to assist member countries to achieve Millennium Development Goals (MDG). The Government of Mongolia has adopted a National Essential Drug List (NEDL) with the seventh update published in 2014. The objective of this study was to determine the accessibility, availability and costs of essential pediatric medicines in Mongolia. METHODS: A standardized methodology developed by the WHO and Health Action International (HAI) was employed to conduct a study on the availability, costs and affordability of pediatric medicines in Mongolia. A data collection tool collected information in regards to retail and wholesale availability and costs of essential pediatric medicines at pharmacy outlets during January and August of 2016. RESULTS: Availability of individual essential pediatric medicines varied across the country. The average availability of medicines was 72.6% in the public sector (9.1-100%). Correspondingly, average availability of all selected medicines in the private sector was 76.7% (26.7-100%). Lowest price medicines were 2.45 times higher than the international reference price (IRP) in the private sector and was 1.95 times higher in the public sector. The lowest cost medicines in the public sector were more affordable for all conditions. The least affordable treatment was estimated to be for respiratory tract infections, or otitis media using amoxicillin clavulanic acid, suspension costing up to 1.03 days wages. CONCLUSION: Procurement, supply and distribution of essential pediatric medicines needs to be regularly investigated in order to identify the availability and costs of pediatric formulations in Mongolia.Scopus© Citations 12 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Drug pricing and reimbursement decision making systems in Mongolia(Informa UK Limited, 2017) ;Dorj, Gereltuya ;Sunderland, Bruce ;Sanjjav, Tsetsegmaa; BACKGROUND: It is essential to allocate available resources equitably in order to ensure accessibility and affordability of essential medicines, especially in less fortunate nations with limited health funding. Currently, transparent and evidence based research is required to evaluate decision making regarding drug registration, drug pricing and reimbursement processes in Mongolia. OBJECTIVE: To assess the drug reimbursement system and discuss challenges faced by policy-makers and stakeholders. METHODS: The study has examined Mongolian administrative documents and directives for stakeholders and analysed published statistics. Experts and decision-makers were interviewed about the drug pricing and reimbursement processes in Mongolia. RESULTS: Decisions regarding Mongolian drug registration were based on commonly used criteria of quality, safety, efficacy plus some economic considerations. A total of 11.32 billion Mongolian National Tugrugs (MNT) [5.6 million United States Dollars (USD)] or 12.1% of total health expenditure was spent on patient reimbursement of essential drugs. The highest reimbursed drugs with respect to cost in 2014 were the cardiovascular drug group. Health insurance is compulsory for all citizens; in addition all insured patients have access to reimbursed drugs. However, the decision making process, in particular the level of reimbursement was limited by various barriers, including lack of evidence based data regarding efficacy and comparative cost-effectiveness analysis of drugs and decisions regarding reimbursement. CONCLUSIONS: Drug registration, pricing and reimbursement process in Mongolia show an increasing trend of drug registration and reimbursement rates, along with lack of transparency. Limited available data indicate that more evidence-based research studies are required in Mongolia to evaluate and improve the effectiveness of drug pricing and reimbursement policies.Scopus© Citations 7 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prevalence and risk factors of COVID-19 co-infection in TB patients(International Union Against Tuberculosis and Lung Disease, 2025-04) ;Nyamsaikhan, T; ;Erdenee, O ;Jantsansengee, BBadamnachin, B - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country(Springer Science and Business Media LLC, 2020-05); ;Dorj, Gereltuya ;Sunderland, Bruce ;Sanjjav, TsetsegmaaBACKGROUND: High prevalence of falsified, counterfeit and substandard medicines pose a threat to public health and treatment failure. This study aimed to investigate the quality of selected essential medicines available in Mongolia. METHODS: A cross-sectional study collected essential medicines from pharmacy outlets in Mongolia, during June and July, 2017. These products were then submitted for pharmacopoeial analysis and registration status. RESULTS: A total of 1770 samples from 118 pharmacy entities were purchased from wholesalers in urban and rural areas. Pharmacopoeial analysis found 179 (10.1%) samples or eleven product groups were unacceptable. The prevalence of substandard locally produced medicines (n = 105, 5.9%) was higher than imported equivalents [(n = 74, 4.17%, p = 0.0001)]. Approximately one-third of all unacceptable tests were related to assay (n = 73, 30.8%) and weight variation. Of 1770 samples, 76 (4.3%) were unregistered and the prevalence of unregistered samples was 3.8% in Ulaanbaatar city and 5.8% in rural areas, respectively. CONCLUSIONS: This study has indicated that falsified and substandard medicines are prevalent in Mongolia. Considerable effort is required by regulatory authorities, private manufacturers, as well as importers to increase the quality of essential medicines in Mongolia.Scopus© Citations 17
